Intravascular Brachytherapy



Intravascular Brachytherapy





25.1. INTRODUCTION

Since the development of drug-eluting stents (DES), intravascular brachytherapy (IVBT) is being phased out as a primary treatment for restenosis. We debated whether this topic should be included in this edition of the book. However, there have been reports in the recent literature that the use of IVBT after DES can further decrease the likelihood of restenosis. In view of this and the possibility that IVBT may be used in future studies, we have kept the topic in.

Coronary artery disease is most commonly treated using bypass surgery or percutaneous transluminal coronary angioplasty (PTCA). A major problem with PTCA, however, is the high incidence of restenosis and recurrence of artery blockage at the site of treatment. Restenosis is usually arbitrarily defined as a narrowing of the lumen by 50% or greater in diameter compared to the adjacent normal-appearing segments. Although the occurrence of restenosis is significantly reduced by the implantation of coronary stents, the restenosis rate following balloon angioplasty in randomized trials is 30% to 40% (1).

Most restenosis after angioplasty or stenting is caused by thrombosis or blood clotting at the PTCA site, which can be prevented partially by using anticlotting drugs. However, another process, which begins within days after angioplasty, is the neointimal growth of tissues prompted by the wound-healing process following tissue injury by angioplasty. This component of restenosis cannot be prevented by anticoagulants or stents.

Intraluminal irradiation of coronary and peripheral arteries together with balloon angioplasty and/or stent implantation significantly lowers the rate of neointimal formation, thereby reducing the rate of restenosis to well below 10% (2). Radiation kills cells and inhibits the growth of neointimal tissues in a manner similar to its effect on benign diseases such as keloids and heterotopic bone formation. Basic radiation biology and vascular pathology are discussed by several authors (3, 4, 5).


25.2. TREATMENT VOLUME


A. ARTERIAL ANATOMY

The arteries carry blood from the heart to various parts of the body. The main artery, the aorta, is the largest blood vessel (2 to 3 cm in diameter) and carries blood from the left ventricle of the heart to the branching arteries and capillaries in all the body organs and tissues, including the heart muscle. The coronary arteries are blood vessels lying on the outer surface of the heart and the peripheral arteries supply blood to other organs and tissues. The luminal diameter of arteries ranges from 3 to 5 mm initially and tapers slowly through their path length. Within this range, the peripheral arteries tend to be of larger diameter than the coronary arteries. The minimum normal artery diameter required for angioplasty and stenting is approximately 3 mm.

The inside of the arteries is lined with a layer of cells called endothelium. Next to the endothelium is the connective tissue layer, the intima, followed by layers of elastic membrane, smooth muscle cells, and elastic tissues. The outermost layer of the arteries is called adventitia, made up chiefly of collagenous fiber.


B. ANGIOPLASTY AND RESTENOSIS

The arteries can be partially blocked due to atherosclerosis or plaque formation. Reduction of their lumen diameter compromises the flow of blood and the delivery of oxygen to the body tissues. As an alternative to a major surgical procedure such as bypass surgery, balloon angioplasty
is used to dilate the lumen diameter. This stretching action often ruptures the internal elastic lamina of the wall and causes fissures in the medial layers. The acute risk of the angioplasty procedure is thrombosis that can be controlled by drugs, as mentioned previously. The more protracted risk, however, is that of restenosis by neointimal hyperplasia. This process involves growth of new tissues in the cracks and crevices of the arterial wall caused by angioplastic injury. Although implantation of stent angioplasty reduces the overall rate of restenosis by approximately 50%, it does not prevent neointimal growth and may, in fact, stimulate the process.


C. TARGET VOLUME

Target volume for IVBT is confined to the region of angioplasty. Typically, it is 2 to 5 cm in length of artery and 0.5 to 2 mm in thickness of arterial wall. Occasionally, these dimensions may be exceeded depending on the location and extent of the disease. With 3 to 5 mm of luminal diameter, the radial range of treatment may extend as far as to about 5 mm from the center of the artery.

Because of the severity of inverse square falloff of radiation at short distances, transluminal irradiation with IVBT produces highly conformal dose distribution, delivering a high dose to the arterial wall while sparing surrounding normal vessels or myocardium. Again, because of the predominance of the inverse square law effect, penetrating power of radiation, depending on energy and modality, is not critically important, except with regard to dose rate or duration of implant and radiation protection of personnel involved with the procedure. β-Particle sources, in general, give higher dose rates and provide greater radiation protection compared to the γ-ray sources.

The depth of dose prescription for intracoronary irradiation is recommended by the American Association of Physicists in Medicine (AAPM) (6) to be 2 mm from the center of the source and for the peripheral arteries 2 mm beyond the average lumen radius. For each case, dose distribution in at least three planes perpendicular to the catheter and along its length should be determined. In addition, average, maximum, and minimum doses within the target volume should be reported (6).


25.3. IRRADIATION TECHNIQUES

IVBT techniques may be classified into two categories: temporary implants (sealed sources or liquid-filled balloons) and permanent implants (radioactive stents). Each method has its advantages and limitations, but the catheter-based sealed source is the preferred method because of its better control of dose delivery. A variety of β- and γ-ray sources have been used for endovascular therapy, although the choice of one modality over the other is yet not clearly established. The pros and cons of a few sources and devices are discussed below.


A. RADIATION SOURCES

Typical dosimetric requirements of a temporary intravascular implant are (a) to deliver a target dose of 15 to 20 Gy to a 2- to 3-cm length of the arterial wall involved at a radial distance of about 2 mm from the source center, (b) to minimize the dose to tissues outside the region of angioplasty, and (c) to take as little time as possible for completion of the procedure, that is, provide target dose rates on the order of 5 Gy/min or greater. These requirements suggest the suitability of high-energy β sources such as strontium-90, yttrium-90, and phosphorus-32 or high-activity γ sources such as iridium-192. The latter could be a high-dose-rate (HDR) afterloading unit with the source dimensions small enough to allow IVBT.

The β sources have several advantages over γ sources: higher specific activity, higher dose rate, longer half-life, and greater radiation safety for the patient as well as personnel. The major disadvantage of β sources, however, is the extremely rapid radial dose falloff within the target region; γ sources such as 192Ir provide relatively more uniform target dose, governed primarily by the inverse square law falloff with distance, but require high activity to yield a reasonably high dose rate (≥5 Gy/min). Consequently, radiation protection problems with such sources become more significant. Although the HDR afterloaders using γ sources could provide sufficiently high dose rate, they would require expensive shielding of the catheterization laboratories.

Table 25.1 contains a list of possible isotopes that have been or could be used for IVBT. The last column shows the activities required to obtain a dose rate of 5 Gy/min to a 2-cm length of a vessel at a radial distance of 2 mm from the source center. It is seen that the γ sources, because of lower specific activity, require much higher activities than the β sources for a catheter-based intravascular procedure. On the other hand, a permanent radioactive stent using 48V requires only 1 µCi to produce the same dose rate.









TABLE 25.1 Possible Isotopes for Intraluminal Brachytherapy





























































Isotope


Emission


Maximum Energy (keV)


Average Energy (keV)


Half-Life


Activity Required


Ir-192


γ


612


375


74 d


1.0 Ci (37 GBq)


Iodine-125


X-ray


35


28


60 d


3.8 Ci (140.6 GBq)


Palladium-103


X-ray


21


21


19 d


3.9 Ci (144.3 GBq)


Phosphorus-32


β


1,710


690


14 d


40.0 mCi (1,480 MBq)


Strontium/yttrium-90


β


2,270


970


28 y


30.0 mCi (1,110 MBq)


Tungsten/rhenium-188


β


2,130


780


69 d


35.0 mCi (1,295 MBq)


Vanadium-48


β+


690


230


16 d


1.0 µCi (37 Bq) stent


(From Amols HI. Physics and dosimetry of intravascular brachytherapy. In: Thomadsen B, ed. Categorical Course in Brachytherapy Physics. Oak Brook, IL: Radiological Society of North America; 1997, with permission.)


Although dose rate per unit-activity favors β emitters, radial dose distribution is better for the γ sources, if it is assumed that the dose uniformity across the target volume is radiobiologically beneficial. This assumption has not been clinically validated but it seems logical, based on experience in conventional radiation therapy. Figure 25.1 compares radial dose distribution as a function of radial distance for some of the sources listed in Table 25.1. Nath and Liu (7) have studied radial dose function (g) for point sources of photons and electrons using Monte Carlo simulation. Their data show that from the point of view of adequate depth of penetration for IVBT, photon sources above 20 keV and electron sources above 1.0 MeV are acceptable.


B. RADIATION DELIVERY SYSTEMS

Irradiation of blood vessels to prevent restenosis following angioplasty has been carried out using external beam as well as brachytherapy. A number of catheter-based endovascular systems have become available commercially. Of these, the U.S. Food and Drug Administration has approved only a few for clinical use. A brief review of some of the available devices is presented below. For more detailed product information and specifications, the reader is referred to the respective company literature.


B.1. Novoste Beta-Cath

The Novoste Beta-Cath System1 uses β sources of 90Sr/90Y isotope. It is a manual afterloader device with a catheter-based delivery system. The system consists of two main components: (a) a transfer device for housing and hydraulic delivery of a radiation source train and (b) a delivery catheter to transport the source train.

The delivery catheter (Fig. 25.2) has three lumens. The first lumen is used for travel of the guidewire. The second lumen is for transport of the source train consisting of sealed cylindrical seeds of 90Sr/90Y. The source train is delivered to the distal end of the delivery catheter by applying manual hydraulic pressure through a syringe, which contains sterile water and is attached to the transfer device. The third lumen, which is also attached to the transfer device, is designed
to provide an opposite hydraulic pressure for returning the source train back into the storage position of the transfer device.






Figure 25.1. Radial dose falloff with distance for a number of sources. Doses are normalized to 1 at a radial distance of 2 mm. (From Amols HI, Zaider M, Weinberger J, et al. Dosimetric considerations for catheter-based β and γ emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys. 1996;36:913-921, with permission.)






Figure 25.2. Novoste Beta-Cath 3.5 System with source train and transfer device. (Courtesy of Novoste: www.novoste.com.)

The major advantage of the Novoste system is its use of the 90Sr/90Y source, which is one of the highest-energy β emitters with a long half-life (28 years). Other advantages include high dose rate (treatment time approximately 5 minutes), patient and personnel safety, and simplicity of the handheld transfer device. The major disadvantage is the lack of a catheter-centering device, which could result in extreme dosimetric hot and cold spots within the target volume.


B.2. β-Emitting Liquid-Filled Balloon

An alternative to catheter-based wires and seeds is to inflate the balloon dilation catheter with β-emitting radioactive liquid. The advantages of a liquid-filled balloon are inherent source centering and dose uniformity to the vessel wall. Several β-emitting isotopes such as 32P, 90Y, and 188Re, which can be obtained in a liquid radiopharmaceutical preparation, may be used in this technique.

The major disadvantages of liquid-filled balloons include (a) higher ratio of surface/adventitial dose compared to the catheter based γ-source systems and (b) the possibility, although remote, of balloon rupture and consequently leakage of radioisotope within the patient. Of the radioisotopes mentioned previously, the rhenium-188 formulation is preferable because of the reduced radiation dose to organs such as colon and thyroid due to its rapid renal elimination in the event of balloon rupture. 188Re also has a favorable maximum β energy (2.13 MeV).

One of the liquid-filled balloon devices was developed at the Columbia University/Oak Ridge National Laboratory (8). The system uses a liquid preparation of 188Re (188Re-MAG3), which is obtained at high specific activities from a tungsten (188W) generator and delivered into a perfusion angiography balloon. A commercial system (RADIANT2) also uses a 188Re-filled balloon and is similar to conventional balloon PTCA (Fig. 25.3). It may be used before or after stent placement.


B.3. Radioactive Stents

Jun 8, 2016 | Posted by in GENERAL RADIOLOGY | Comments Off on Intravascular Brachytherapy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access